

## ESMO 2019 Industry Satellite Symposium

Monday, 30 September | 18:30-20:00

Cartagena Auditorium, Hall 3

Fira Gran Via, Barcelona, Spain

# Taking the Next Step in Lung Cancer:

## Combination Approaches with Immune Checkpoint Inhibition

To learn more about AstraZeneca,  
visit us at **Booth #305**.



### FACULTY PRESENTERS

#### Fabrice Barlesi, MD, PhD

Aix Marseille University –  
Assistance Publique Hôpitaux  
de Marseille  
France

#### David Gandara, MD

UC Davis  
Comprehensive Cancer Center  
United States

#### Silvia Novello, Prof, MD, PhD

University of Turin  
Italy

#### David Spigel, MD

Sarah Cannon  
Research Institute  
United States



### Agenda

- 18:30–18:35** Introduction and Opening Remarks
- 18:35–18:50** Evolving Role of Immune Checkpoint Inhibitors in First-Line Extensive-Stage SCLC
- 18:50–19:05** Emerging Biomarkers with Potential to Aid in Treatment Decisions in First-line Metastatic NSCLC
- 19:05–19:20** Novel Combination Approaches with Immune Checkpoint Inhibitors in First-line Metastatic NSCLC
- 19:20–19:55** Incorporating Combination Regimens into Clinical Practice: Patient Cases with Panel Discussion
- 19:55–20:00** Closing Remarks



### Meeting Objectives

- Evaluate the available clinical data on the use of immune checkpoint inhibitors as first line treatment for extensive-stage small cell lung cancer (SCLC)
- Evaluate combination approaches with immune checkpoint inhibitors as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC)
- Evaluate the impact of emerging biomarkers on the use of immune checkpoint inhibitors as first-line treatment of metastatic NSCLC

*Don't miss our interactive panel discussion!*

*This is a scientific exchange event provided  
by AstraZeneca Pharmaceuticals.*

**AstraZeneca**